Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corine Bernaud

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Therapie|August 8, 2014
Information and communication on risks related to medications and proper use of medications for healthcare professionals and the general public: precautionary principle, risk management, communication during and in the absence of crisis situationsMathieu Molimard, Corine Bernaud, Philippe Lechat, et al.
Therapie|July 10, 2016
[Not Available]Mathieu Molimard, Corine Bernaud, Philippe Lechat, et al.
European Heart Journal|January 30, 2020
Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromesRobert F Storey, Paul A Gurbel, Jurrien Ten Berg, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Therapie|August 8, 2014
Information and communication on risks related to medications and proper use of medications for healthcare professionals and the general public: precautionary principle, risk management, communication during and in the absence of crisis situationsMathieu Molimard, Corine Bernaud, Philippe Lechat, et al.
Therapie|July 10, 2016
[Not Available]Mathieu Molimard, Corine Bernaud, Philippe Lechat, et al.
European Heart Journal|January 30, 2020
Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromesRobert F Storey, Paul A Gurbel, Jurrien Ten Berg, et al.
Pageof 2